Patents by Inventor David A. Byron

David A. Byron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240245655
    Abstract: In an aspect, the invention relates to compositions and methods for treating sepsis, including but not limited neonatal sepsis and sepsis related to infection. In an aspect, the invention relates to compositions and methods for attenuating adverse conditions of sepsis resulting from enterovirus infection. In an aspect, the invention relates to improved formulations of antiviral agents such as pleconaril for the treatment, alleviation and prevention of conditions associated with sepsis.
    Type: Application
    Filed: April 4, 2024
    Publication date: July 25, 2024
    Applicant: Antivirus Therapeutics
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20240139159
    Abstract: Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picomaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 2, 2024
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20220202784
    Abstract: Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picomaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril.
    Type: Application
    Filed: March 17, 2022
    Publication date: June 30, 2022
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20210322389
    Abstract: In an aspect, the invention relates to compositions and methods for treating sepsis, including but not limited neonatal sepsis and sepsis related to infection. In an aspect, the invention relates to compositions and methods for attenuating adverse conditions of sepsis resulting from enterovirus infection. In an aspect, the invention relates to improved formulations of antiviral agents such as pleconaril for the treatment, alleviation and prevention of conditions associated with sepsis.
    Type: Application
    Filed: May 27, 2021
    Publication date: October 21, 2021
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20200405698
    Abstract: Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picornaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 31, 2020
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20200155517
    Abstract: Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picomaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril.
    Type: Application
    Filed: January 22, 2020
    Publication date: May 21, 2020
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20190343811
    Abstract: In an aspect, the invention relates to compositions and methods for treating sepsis, including but not limited neonatal sepsis and sepsis related to infection. In an aspect, the invention relates to compositions and methods for attenuating adverse conditions of sepsis resulting from enterovirus infection. In an aspect, the invention relates to improved formulations of antiviral agents such as pleconaril for the treatment, alleviation and prevention of conditions associated with sepsis.
    Type: Application
    Filed: July 10, 2019
    Publication date: November 14, 2019
    Inventors: Anand Gumaste, David A. Byron
  • Publication number: 20190321340
    Abstract: Compositions and method of the present invention comprise novel formulations for increasing the effectiveness of antiviral agents and for preventing and treating symptoms associated with the common cold and viral infections. The present invention is directed to treating symptoms resulting from viral infections and diseases associated with Picomaviridae, Coronaviridae, Orthomyxoviridae, Paramyxovirinae, Reoviridae, and Adenoviridae. The novel formulations provided herein improve the therapeutic ratio of antiviral agents such as pleconaril.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 24, 2019
    Inventors: Anand Gumaste, David A. Byron
  • Patent number: 9119777
    Abstract: The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 1, 2015
    Assignee: MICRODOSE THERAPEUTX, INC.
    Inventors: Robert Cook, David A. Byron, Scott Fleming
  • Publication number: 20150238456
    Abstract: The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Robert Cook, David A. Byron, Scott Fleming
  • Publication number: 20120077786
    Abstract: Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.
    Type: Application
    Filed: September 27, 2011
    Publication date: March 29, 2012
    Inventors: David A. Byron, Alan B. Watts, Robert O. Cook, Murat Aydin
  • Patent number: 4820306
    Abstract: The invention comprises a syringe for extrusion of a semi-plastic mass, or a mass having a paste-like consistency. In a preferred embodiment, the syringe is so-designed to permit mixing of two components of a plasticizable mixture within the syringe barrel. The bore of the syringe barrel is flared to facilitate extrusion of the plastic mass therefrom. The parts of the syringe ready for use are packaged in a one-piece tray which serves not only for shipping and storing of the syringe, which may be preloaded with one of the components of the plasticizable mixture, together with the associated syringe parts, but which also serves, when opened for use, as a convenient tray for handling the syringe while mixing the two components of the plasticizable mixture prior to extrusion.
    Type: Grant
    Filed: January 23, 1984
    Date of Patent: April 11, 1989
    Assignee: Sterling Drug Inc.
    Inventors: William G. Gorman, David A. Byron
  • Patent number: 4551135
    Abstract: The invention comprises a syringe for extrusion of a semi-plastic mass, or a mass having a paste-like consistency. In a preferred embodiment, the syringe is so-designed to permit mixing of two components of a plasticizable mixture within the syringe barrel. The bore of the syringe barrel is flared to facilitate extrusion of the plastic mass therefrom. The parts of the syringe ready for use are packaged in a one-piece tray which serves not only for shipping and storing of the syringe, which may be preloaded with one of the components of the plasticizable mixture, together with the associated syringe parts, but which also serves, when opened for use, as a convenient tray for handling the syringe while mixing the two components of the plasticizable mixture prior to extrusion.
    Type: Grant
    Filed: May 19, 1982
    Date of Patent: November 5, 1985
    Assignee: Sterling Drug Inc.
    Inventors: William G. Gorman, David A. Byron